Cultivate Biologics Logo

Introducing Science + Consistency to Botanical Ingredients

Research Drives Discovery

From the characterization and stability of our complex hemp extracts, to in-depth in vitro RNA-seq analyses, our research initiatives illuminate the intricate world of cannabinoids. Cultivate’s groundbreaking pharmacokinetic studies are conducted in collaboration with esteemed institutions such as Cornell University, Washington State University, and Johns Hopkins Medical. span diverse species, including humans. As leaders in cannabinoid exploration, our commitment to advancing therapeutic understanding remains unwavering. This mission extends to advancing our science discoveries with other botanicals that show promise to human and animal health.

Characterization

We’ve achieved 97% Characterization in Partnership with the University of Colorado, Boulder, and Tel Aviv University. Our Complex Hemp Extract, Predominantly Cannabinoid Acids, Reveals Terpenes, Distinct Flavonoids, Plant Lipids, and Unidentified Cannabinoids – Replicated with Reliability and Precision.

Similar Characterization for Terpenes and Flavonoids

Extract Characterization
Cannabinoid Acid Characterization
Who We Are

We at Cultivate are scientists and researchers, plant geneticists and business leaders. To be the best for our customers we need expertise in all areas of the camabinoid business, not just growing the best plants. Cultivate employees are known in their respective fields for being the best and when you bring the best together, great things happen. We have partnerships and studies ongoing with leading research institutions, such as Johns Hopkins Medical, Oregon State University, and Washington State University. We are committed to using knowledge to expand the possibilities in cannabinoid products and to change the conversation about cannabinoids. Our goal is to make cannabinoid products for our customers that are so good, they will change the industry for the better.

Our Infrastructure

Cultivate maintains the highest standards of quality and consistency in our formulations and product development due to our in-house analytical capabilities, exceptional third party testing partners, combined with our quality control protocols that meet GMP 21 CFR 111 And 117 standards for food and supplements. We are able to test every batch of oil we produce in a matter of hours for both cannabinoids and terpenes with our High Performance Liquid Chromatography (HPLC) and Gas Chromatography (GC) systems. 

Christian Kjaer

Christian Kjaer

Board Chair & CEO

Former senior executive at IDEXX Laboratories: President of OPTI Medical Systems; VP and GM of Water Division; VP and GM of South Asia/Middle East/Africa Region. Former CEO of European tech companies. Christian is also Board Chair and CEO of ElleVet Sciences and TevElle Pharmaceuticals and holds a Master of Business from Copenhagen Business School.

 

Stability

Defying Common Beliefs in Cannabinoid Research, our research challenges the notion of CBDA instability. Contrary to common belief, we’ve demonstrated the exceptional stability of CBDA within our exclusive patented formulation.

The Cannabinoid Acids Were Shown to be Stable

Stability Data Chart
table

This product is highly stable through an 8-month period with a 5% (by weight) decarboxylation of total cannabinoid content after 15 months.

More significant decarboxylation is observed after two years, with 12% (by weight) decarboxylation of total cannabinoid content at 27 months.

Unraveling the Physiological Effects of Our Biologically Active Extracts

We are currently engaged in in vitro research, aiming to discern the physiological effects of the biologically active compounds present in our extracts. This focused exploration seeks to identify and understand the intricate ways in which these compounds interact with cellular processes. By unraveling the physiological impact at the cellular level, we aim to pave the way for a deeper comprehension of the therapeutic potential inherent in our formulations.

 

mRNA Screen

Source: Ric Scalzo Institute for Botanical Research

Genomic studies performed with Sonoran University’s Ric Scalzo Institute for Botanical Research

In collaboration with  Ric Scalzo Institute for Botanical Research, we utilize RNA-seq analysis to examine the messenger RNA (mRNA) in our samples, assessing its differential expression. Notably, changes in mRNA expression, as identified through these studies, signify potential biological significance. These alterations are likely linked to corresponding changes in protein levels, offering valuable insights into the functional impact of our samples on cellular processes.

Potential Implications for Neural Function

Preliminary findings suggest an impact on neurotransmitters such as Dopamine and Glutamate, signaling potential implications for neural function. Furthermore, our investigation reveals modulation in pathways associated with inflammation and neoplasia, shedding light on the intricate ways in which our samples influence critical cellular processes. These insights mark significant progress in understanding the potential therapeutic effects of our formulations at a molecular level.

Source: Ric Scalzo Institute for Botanical Research

Bioavailability

At Cultivate Biologics, we are unraveling the complexities of cannabinoid extract bioavailability. Through human pharmacokinetic studies at Washington State University (WSU) and Johns Hopkins University (JHU), as well as a wide range of cross-species pharmacokinetic studies, we’ve discovered the superior absorption of cannabinoid acids. Our research also highlights the nuanced nature of absorption and metabolism across different species which is significant.

CBD:CBDA

CBDA = 45x Absorbtion
CBDA is absorbed 45x more than CBD when Cultivate Biologics BioD is dosed at 1mg/kg in a human model.

CBG:CBGA

CBGA = 30x Absorbtion
CBGA levels were 30x higher concentration than CBG when Cultivate’s BioD blend was administered in a human model.

THC:THCA

THCA = 40x Absorbtion
THCA levels were 40x higher than THC when Cultivate’s BioD blend was administered in a human model.
CBDA 45x

CBDA is Absorbed 45x Greater Than CBD

Given equal doses of CBD and CBDA, the acidic form absorbs 45 times greater than the CBD. CBDA also reaches its highest CMax level thirty minutes prior to CBD, showing similar onset of action to nano/lipohilic formulations.
species & format

Cultivate Leads in Cannabinoid Research Across Species

Absorption & Metabolism Vary Dramatically Across Species

Cultivate Biologics BioD full spectrum extract has been used in studies across a number of species and delivery formats. While CBDA consistently proves to be more bioavailable than CBD isolates, the results vary widely. Cultivate’s experience in clinical research specific to full spectrum cannabinoid extracts is leading the way in terms of developing cannabinoid-based human and animal therapies.

species matter chart